PCV48 Systematic Review of Cost-Effectiveness Models for Pharmacologic Stroke Prevention in Atrial Fibrillation

Value in Health - United Kingdom
doi 10.1016/j.jval.2012.08.991
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Oral Anticoagulants for Prevention of Stroke in Atrial Fibrillation: Systematic Review, Network Meta-Analysis, and Cost Effectiveness Analysis

British Medical Journal
Medicine
2018English

Cost-Effectiveness of Apixaban for Stroke Prevention in Non-Valvular Atrial Fibrillation in Saudi Arabia

Annals of Saudi Medicine
Medicine
2019English

Stroke Prevention in Atrial Fibrillation

Journal of Atrial Fibrillation
Cardiovascular MedicineCardiology
2010English

Stroke Prevention in Atrial Fibrillation

International Journal of Arrhythmia
2017English

Cost-Effectiveness of Apixaban Compared With Aspirin for Stroke Prevention in Atrial Fibrillation Among Patients Unsuitable for Warfarin

Circulation. Cardiovascular quality and outcomes
MedicineCardiovascular MedicineCardiology
2012English

Cost-Effectiveness Analysis of Apixaban Against Warfarin for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation in Japan

Clinical Therapeutics
Pharmacology
2015English

Pcv84 - Cost-Effectiveness Analysis of Apixaban Versus Edoxaban for Stroke Prevention in Non-Valvular Atrial Fibrillation Spanish Patients

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Cost-Effectiveness of Rivaroxaban for the Prevention of Stroke in Patients With Non-Valvular Atrial Fibrillation – A Multinational Study

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Stroke Prevention in Atrial Fibrillation Trial

Circulation
Cardiovascular MedicinePhysiologyCardiology
1991English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy